Jacob P Thyssen

• MD PhD DmSci
• Consultant at Copenhagen University Hospital Herlev-Gentofte

Background Treatment optimization may require dosing flexibility. The Phase 3 JADE REGIMEN trial (NCT03627767) evaluated maintenance of abrocitinib 200 mg‐induced response in patients with moderate‐to‐severe atopic dermatitis (AD) randomly assigned to subsequent maintenance with continuous‐dose abrocitinib (200 mg), reduced‐dose abrocitinib (100 mg...

Background Although rare, allergic reactions to metal implants represent a diagnostic challenge in view of missing guidelines. Objectives To develop an European expert consensus on characteristics of metal allergy reactions and the utility of various diagnostic tools in suspected metal implant allergy. Methods A nominal group technique (NGT) was...

Atopic dermatitis (AD), the most burdensome skin condition worldwide, is influenced by climatic factors and air pollution; however, the impact of increasing climatic hazards on AD remains poorly characterized. Leveraging an existing framework for 10 climatic hazards related to greenhouse gas emissions, we identified 18 studies with evidence for an...

Background Little is known about the therapeutic benefits of a value‐based healthcare model compared to a traditional activity‐based incentive model in psoriasis (PsO). Objectives This prospective non‐interventional study evaluated an outcome‐based, patient‐centred management model for patients with PsO. Methods In total, 49 patients with a Psori...

Background: Atopic dermatitis (AD) endotypes differ with ethnicity. We examined the skin microbiota, cytokine-, and lipid-profiles in Greenlandic Inuit and Danish children with AD. Methods: 25 Inuit children with AD and 25 Inuit control children were clinically examined and compared to previously collected data from 25 Danish children with AD. S...

Treating atopic dermatitis (AD) in pregnant or breastfeeding women, and in women and men with AD aspiring to be parents is difficult and characterized by uncertainty, as evidence to inform decision‐making on systemic anti‐inflammatory treatment is limited. This project mapped consensus across dermatologists, obstetricians, and patients in North‐wes...

Background: Atopic dermatitis (AD) is a heterogeneous inflammatory skin disease with different clinical phenotypes based on factors such as age, race, comorbidities, and clinical signs and symptoms. The effect of these factors on therapeutic responses in AD has only been scarcely studied and not for upadacitinib. Currently, there is no biomarker p...

Atopic dermatitis (AD) and food allergy (FA) share similar type 2 inflammation and commonly co‐occur, but the precise proportion of AD patients with FA and vice versa, as well as the effect of AD disease severity on the strength of this association remains uncertain. The aim of this comprehensive systematic review and meta‐analysis was to determine...

Despite the emergence of novel targeted treatments for atopic dermatitis (AD), there is a lack of guidelines on standardizing analysis of clinical trial data. To define and estimate meaningful treatment comparisons, several factors, including intercurrent events, must be taken into account. Intercurrent events are defined as events occurring after...

Background: Evaluation of effectiveness and safety of new systemic treatments for atopic dermatitis (AD) after approval is important. There are few published data exceeding 52-week therapy with dupilumab. Objectives: To examine the safety, effectiveness, and drug survival of dupilumab in a Danish nationwide cohort with moderate-to-severe AD up t...

Background Baricitinib demonstrated efficacy in treating adults with moderate-to-severe atopic dermatitis (AD) in Phase3 clinical trials. Objective To examine long-term efficacy of baricitinib combined with topical corticosteroids (TCS) in adult patients from a Phase3 study, BREEZE-AD7 (NCT03733301), enrolled in ongoing extension study, BREEZE-AD3...

Background: Rosacea is a common chronic inflammatory facial skin disorder. Standardized evaluation of the severity and extent of rosacea is important for baseline assessment and treatment effect. The currently used Investigator's Global Assessment (IGA) is unspecific and fails to consider subtypes/phenotypes of rosacea and area involvement. The Ro...

Background: Atopic dermatitis (AD) and asthma often co-occur in the same patient, and health care utilization is related to disease severity of these diseases. Objective: To investigate differences in healthcare utilization in adults with concomitant AD and asthma compared to patients with asthma or AD only. Methods: All Danish adults with a h...

Background: Paediatric atopic dermatitis (AD) can be burdensome, affecting mental health and impairing quality of life for children and caregivers. Comprehensive guidelines exist for managing paediatric AD, but practical guidance on using systemic therapy is limited, particularly for new therapies including biologics and Janus kinase (JAK) inhibit...

Atopic dermatitis (AD) is a chronic skin disease that significantly impacts patient quality of life (QoL). It is unknown whether patients and physicians have the same interpretation of AD burden. Unmet needs and AD disease burden were evaluated by comparing terminology used in social media with terminology used in scientific literature. AD terminol...

Background Drug survival is an important proxy measure for effectiveness of treatments for inflammatory diseases such as rheumatoid arthritis (RA), axial spondyloarthritis (AxSpA), psoriatic arthritis (PsA), and psoriasis [1-4]. Objectives The objective of this study was to examine the real-life drug survival of biologics and novel small-molecule...

Background: Once-daily abrocitinib treatment provided meaningful improvements in signs and symptoms of moderate-to-severe atopic dermatitis (AD) in randomized controlled studies. Objective: To evaluate proportions of patients with responses meeting higher threshold efficacy responses than commonly used efficacy endpoints and to determine if thes...

Contact dermatitis is a common disease, caused by repeated skin contact to contact allergens or irritants, resulting in allergic contact dermatitis (ACD) and/or irritant contact dermatitis. Attempts have been made to identify biomarkers to distinguish irritant and allergic patch test reactions, which could aid diagnosis. Some promising candidates h...

Dear Editor, Omalizumab is a monoclonal antibody that targets free IgE, inhibiting its interaction with the IgE receptor. It is administered subcutaneously to treat antihistamine‐unresponsive chronic urticaria (CU), allergic asthma that is inadequately controlled with inhaled corticosteroids, and nasal polyps inadequately controlled by nasal cortic...

Background Ocular surface diseases (OSDs), including conjunctivitis and blepharitis, are common in atopic dermatitis (AD) patients, but the magnitude and patient characteristics are unclear. Objectives To examine the prevalence of OSDs in adults with AD and identify patient characteristics and risk factors. Methods We designed a cross-sectional q...

Background In JADE COMPARE, abrocitinib improved severity of atopic dermatitis (AD) and demonstrated rapid itch relief. Objectives We examined clinically meaningful improvements in selected patient-reported outcomes (PROs). Methods JADE COMPARE was a multicentre, phase 3 randomised, double-blind, placebo-controlled trial. Adults with moderate-to-...

Background The cytokine profile of atopic dermatitis (AD) depends on age, ethnicity, and disease severity. This study examined biomarkers in children with AD collected by tape strips and skin biopsies, and examined whether the levels differed with filaggrin genotype, disease severity, and food allergy. Methods Twenty‐five children aged 2–14 years...

Background Occupational hand eczema is common among hairdressers and implementing effective preventive measures requires a good understanding of the disease’s epidemiology. Objective To investigate the long-term development of hand eczema (HE) in hairdressers. Methods A prospective cohort study of all hairdressers graduating from Danish hairdress...

Background Previous studies found conflicting results about the association of atopic dermatitis (AD) with hypertension. Objectives Determine whether AD and AD severity are associated with hypertension. Methods A systematic review was performed of published studies in MEDLINE, EMBASE, Scopus, Web of Science, and GREAT databases. At least 2 review...

Given the lack of head‐to‐head studies of systemic therapies in moderate‐to‐severe atopic dermatitis (AD), network meta‐analyses (NMAs) can provide comparative efficacy and safety data to inform clinical decision making. In this NMA, eligible randomized controlled trials (RCTs) published before October 24, 2019 were identified by a systematic liter...

The prevalence of atopic dermatitis (AD) varies across the globe, and the clinical phenotype with racial background and ethnicity. AD in the Arctic region has only been scarcely studied. We performed a systematic review and meta‐analysis to examine the prevalence, clinical manifestations and risk factors for AD among children and adolescents in the...

Since the introduction of active vaccination against SARS‐CoV‐2 infection, there has been a debate about the risk of developing severe allergic or anaphylactic reactions among individuals with a history of allergy. Indeed, rare cases of severe allergic reactions have been reported in the United Kingdom and North America. By february 2021 a rate of...

Background: Infections can trigger worsening of atopic dermatitis (AD). Objectives: To examine whether hospital-managed paediatric AD is associated with increased risk of extracutaneous infections requiring hospitalization in childhood. Methods: A nationwide-based cohort study using Danish registries was done. Children aged < 18 years with a h...

Background While adult atopic dermatitis (AD) is associated with anxiety and depression and pediatric AD is linked to attention deficit hyperactivity disorder, the relationship between AD in childhood and other psychiatric disorders is largely unknown. Objectives To determine the relationship between AD and diagnosis and treatment of psychiatric d...

Introduction La monothérapie par le baricitinib, un inhibiteur sélectif des JAK1/2, a réduit efficacement la gravité de la DA modérée à sévère lors de précédentes études de phase 3. L’étude de phase 3 en double aveugle, randomisée et contrôlée par placebo BREEZE-AD7 (NCT03733301) a évalué l’efficacité et la sécurité du baricitinib associé à des TCS...

Introduction Les patients atteints de dermatite atopique (DA) ont un risque augmenté d’infections cutanées. Une association potentielle entre DA de l’adulte et infections extra-cutanées a été évoquée à partir d’études transversales avec diagnostics fondés sur auto-questionnaires. En théorie, les infections cutanées non traitées à Staphylococcus aur...

Background Itch, skin pain, and sleep disturbance are burdensome symptoms in atopic dermatitis (AD) that negatively influence a patient’s quality of life (QoL). Objective To evaluate the impact of baricitinib on patient-reported outcomes (PROs) in adult patients with moderate-to-severe AD, and explore the association between improvement in key sig...

Atopic dermatitis (AD) is a highly pruritic, chronic inflammatory skin disease. The diagnosis is made using evaluated clinical criteria. Disease activity and burden are best measured with a composite score, assessing both objective and subjective symptoms, such as SCORing Atopic Dermatitis (SCORAD). AD management must take into account clinical and...

Background Atopic dermatitis (AD) is a prevalent chronically relapsing inflammatory skin disease of childhood. However, little is known about self‐reported trigger factors, impact on daily life and factors associated with AD severity. Methods A nationwide questionnaire study of children in Denmark with hospital‐diagnosed AD in the time period 2014...

Atopic dermatitis (AD) is a complex and heterogeneous chronic inflammatory skin disease. A subset of patients require systemic immunosuppressants including cyclosporine A (CsA), azathioprine (AZA), mycophenolate mofetil (MMF)/mycophenolic acid (MPA), and methotrexate (MTX).1 Dupilumab is the first biologic for treatment of AD, mostly started in pat...

During the COVID‐19 pandemic of Spring 2020, Denmark was one of the first countries to introduce lockdown measures. This included closing of all schools throughout Denmark by 16 March 2020. Primary schools were reopened on 15 April 2020 for grades zero to five. Specific hand hygiene guidelines were issued by the Danish Health Authorities to prevent...

特应性湿疹(也称为“特应性皮炎”或简称“湿疹”)是一种常见的皮肤病。大多数患有特应性湿疹的人可以通过局部治疗(直接涂抹在皮肤上)来控制湿疹,比如润肤剂和局部皮质类固醇。 然而,一些患有中度至重度疾病的患者,不能用这些疗法很好地治疗疾病。这些人需要使用片剂或注射剂进行全身药物治疗(作用于全身的治疗),以有效减轻他们的症状。 Dupilumab 是一种新的全身性药物 (自 2018 年以来), 用于治疗中度至重度湿疹患者。它已经在美国和欧盟获批用于治疗 12 岁或以上的患者。 为了比较 Dupilumab 与其他全身药物治疗的安全性,研究人员需要所有这些药物在实际应用中的安全性数据。TREAT 登记工作组的登记处收集了所有全身药物治疗特应性湿疹的有效性和安全性的数据。英国、爱尔兰、美国、德国、荷...

Atopic eczema (also called ‘atopic dermatitis’ or just ‘eczema’) is a common skin disease. Most people with atopic eczema can control their eczema with topical therapies (applied directly to the skin) such as emollients and topical corticosteroids. Some people, however, have moderate‐to‐severe disease that cannot be well managed with those therapie...

Netherton syndrome (NS), ichthyosis linearis circumflexa, is a rare autosomal recessive disorder. NS is caused by pathogenic loss‐of‐function variants in the serine protease inhibitor of Kazal type 5 gene (SPINK5), compromising lymphoepithelial Kazal type 1 inhibitor (LEKTI‐1) function. The unopposed serine protease activity due to reduced LEKTI‐1...

We read with interest the article by Jabbar‐Lopez et al.,1 showing a significant interaction between filaggrin gene (FLG) loss‐of‐function mutations and exposure to domestic water hardness (≤256 mg/L versus >256 mg/L calcium carbonate (CaCO3) on the risk of atopic dermatitis (AD) at 36 months of age.

Background It is well-established that asthma is common in patients with atopic dermatitis (AD). Objectives We performed a systematic review and meta-analysis to determine the prevalence of asthma and respiratory symptoms in individuals with AD, and the association between AD and asthma. Methods At least two authors independently searched the med...

Background: Baricitinib, an oral selective Janus kinase 1 and 2 inhibitor, effectively reduced atopic dermatitis (AD) severity in a Phase 2 study with concomitant topical corticosteroids. Objectives: To evaluate the efficacy and safety of baricitinib in patients with moderate-to-severe AD and an inadequate response to topical therapies. Methods...

A growing number of clinical trials of biological and systemic therapies have been conducted within adult atopic dermatitis (AD). No study has yet examined and meta-analysed the pooled placebo response in AD. We performed a systematic review and meta-analysis to examine the placebo response in clinical trials evaluating the effect of systemic and b...

Background: The use of insulin pump and glucose sensor is advantageous, but unfortunately many experi-ence skin problems. To reduce or overcome skin problems patients use additional products or change their sets pre-termly. Therefore, the aim was to investigate costs related to skin problems. Methods: 263 patients from 4 different hospitals in D...

Linked Article: Maslin et al. Br J Dermatol 2020; 182:300–303.

Introduction BREEZE-AD1 (NCT03334396) et BREEZE-AD2 (NCT03334422) sont les premières de 7 études cliniques de phase 3 évaluant le baricitinib, un inhibiteur des JAK 1/2, dans le traitement de la dermatite atopique (DA) modérée à sévère. Ces études évaluent l’efficacité et la tolérance du baricitinib dans la DA modérée à sévère insuffisamment contrô...

Background: Parental history of atopic disease is a well-established risk factor for development of atopic dermatitis (AD), but several aspects of this association remain unclear. Objective: To determine the association of parental history of atopic disease with AD in offspring. Methods: We searched PubMed and EMBASE through June 2018 for rele...

Similarities and differences in the everyday clinical management of moderate-to-severe atopic dermatitis in Nordic countries are unknown. Using a modified Delphi approach, 15 dermatologists from Denmark, Finland, Norway and Sweden completed face-to-face and online questionnaires and participated in summary discussions to map expert opinion on the c...

Patients with atopic dermatitis (AD) have an increased risk of bacterial skin infections that cause significant morbidity and, if untreated, may become systemic. Staphylococcus aureus (S. aureus) colonizes the skin of most AD subjects and is the most common organism to cause infections. Overt bacterial infection is easily recognised by the appearan...

Quality of care is a central issue in Atopic Dermatitis (AD) management, and different levels of knowledge and skills are expected and required for primary, secondary and tertiary levels of care. AD is a common skin disease affecting up to 15‐20% of children, as well as 2‐5% of adults. Disease severity ranges from mild to very severe, and according...

Background: There is currently no agreed cosmetic series for use across Europe. Objectives: To establish allergens currently tested in local and national cosmetic series. Methods: Members of ESSCA and COST TD1206 were surveyed to establish their current practice. Results: A wide range of allergens were tested but there was significant variat...

Background: There is debate whether psoriasis and atopic dermatitis (AD) belong to the same disease spectrum. Objectives: To describe and compare disease characteristics, life-style factors and disease burden in adult patients with psoriasis and AD. Methods: We linked registry data with clinical and patient reported outcomes from the Danish Sk...

Atopic dermatitis (AD) is a chronic and relapsing inflammatory skin disease.Molecular characterization of AD shows an underlying inflammation with tissue‐infiltration of T helper (TH) 2 cells and increased IL‐4 and IL‐13. The multifaceted roles of IL‐4 and IL‐13 in allergic disease development makes IL‐4Rα an attractive target for treatment strateg...

Linked Article: Forton and De Maertelaer et al. Br J Dermatol 2019; 181:818–825.

Background: Cold and dry climate negatively affects skin barrier functions. This could explain the higher incidence of atopic dermatitis (AD) in Northern countries distant from the equator, as well as the general worsening of AD in Northern European winter months. Although it has been suggested that fall and winter birth is associated with AD, thi...

Background: Adult atopic dermatitis (AD) patients report skin pain, but the relationship with disease severity, anatomical location, and use of pain medication is unclear. Objective: To examine pain in adults with AD. Methods: We performed a cross-sectional study of nationwide health care data and survey data from the Danish Skin Cohort. 3,208...

Background and aims: Epidemiological studies have established an association between psoriasis and inflammatory bowel disease (IBD), i.e. ulcerative colitis (UC) and Crohn's disease (CD) but results are inconsistent. The aim of this study was therefore to quantify the prevalence and association between IBD and psoriasis. Methods: PubMed, Web of...

Several novel biologics are available or in development for moderate-to-severe plaque psoriasis. These drugs may differ in time until Psoriasis Area and Severity Index (PASI) response is obtained. In this systematic review we examined the time to onset of action for interleukin (IL)-17 and IL-23 agents in the treatment of psoriasis. The primary obj...

Background: Atopic dermatitis (AD) normally onsets in childhood and mostly resolves before adolescences. Disease persistence is known to be difficult to study properly, and current predictors are insufficient to identify more than a small fraction of patients at risk. Objective: To study personal AD medicine history as a retrospective marker of...

Background: A long-term prospective observational safety study is essential to fully characterize the safety profile of systemic immunomodulating therapies for patients with atopic eczema. The TREatment of ATopic eczema (TREAT) Registry Taskforce offers a large platform to conduct such research using national registries that collect the same data...

Metal release from total hip replacements (THRs) is associated with aseptic loosening (AL). It has been proposed that the underlying immunological response is caused by a delayed type IV hypersensitivity-like reaction to metals, i.e., metal allergy. The purpose of this study was to investigate the immunological response in patients with AL in relat...

Abstract is missing (Short communication)

Background: Hand eczema is a disease with large variation in clinical presentation and severity. Scoring systems for quantitative severity assessment exist. However, they are observer-dependent. An objective quantitative tool for scoring of hand eczema would improve categorization of hand eczema. Objective: To investigate the usefulness of multi...

Abundant corneocyte surface protrusions, observed in patients with atopic dermatitis with filaggrin loss-of-function mutations, are inversely associated with levels of natural moisturizing factors (NMFs) in the stratum corneum. To dissect the etiological role of NMFs and filaggrin deficiency in surface texture alterations, we examined mouse models...

Atopic dermatitis (AD) is a common inflammatory skin disease that affects both children and adults, including a large number of adults of reproductive age. Several guidelines for the treatment of AD exist, yet specific recommendations for the treatment of pregnant or lactating women and for adults planning to have a child are often lacking. This po...

We read with great interest the article by Tizek et al., which suggests that certain skin diseases are more common in Germany than previously thought. We were particularly interested in the finding that 25.5% of study participants fulfilled the criteria for rosacea based on dermatologist examination. The authors rightfully suggest that the high ros...

Background: Factors that are associated with patient-reported importance of obtaining complete or almost complete clearance of psoriasis and atopic dermatitis (AD) are unknown. Objectives: To investigate the importance of and factors associated with obtaining complete or almost complete clearance of psoriasis or AD. Methods: A cross-sectional...

Background Cobalt contact allergy is common, but clinical relevance is often difficult to determine. Objectives To examine the aetiology, prevalence and clinical characteristics of cobalt allergic patients who were patch tested between 2002 and 2017 the Department of Dermatology and Allergy, Herlev‐Gentofte Hospital . Methods Patch test data, alo...

Contact allergy to aluminium may develop following vaccination with aluminium‐absorbed vaccines. This article is protected by copyright. All rights reserved.

Background Conjunctivitis is common in patients with atopic dermatitis (AD) in general and a commonly reported adverse event in AD clinical trials with dupilumab. Objective To survey opinions and experience about conjunctivitis occurring in AD, including those during dupilumab treatment in a group of AD experts from the International Eczema Counci...

Allergic nickel dermatitis is frequent and caused by direct skin contact with nickel releasing items such as jewelry.¹ However, other exposures, e.g. at the workplace, may matter and could easily be overlooked. Here we report a nurse with chronic hand eczema caused by occupational nickel exposure, verified by dimethylglyoxime (DMG) testing of metal...

Nickel is the most frequent cause of contact allergy worldwide and has been studied extensively. This clinical review provides an updated overview of the epidemiology, exposure sources, methods for exposure quantification, skin deposition and penetration, immunology, diagnosis, thresholds for sensitization and elicitation, clinical expression, prev...